275 , G984G992 (1998)
Shan, M., You, R., Yuan, X., Frazier, M
Many patients begin compounded semaglutide with high hopes, yet some experience slower-than-expected weight loss or plateau effects after several weeks
The new indication follows positive results in a phase III trial that found children and adolescents living with type 1 diabetes (T1D) achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar events with Toujeo when compared to insulin glargine 100 units/mL (Gla-100)
However, Ozempic is used to treat diabetes, whereas Wegovy is for weight loss
Direct effects on the sinus node have been proposed, and small changes in cardiac conduction have been shown in some studies, although clear arrhythmic risk from semaglutide is not well established